THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDERLINE) RESECTABLE PANCREATIC CANCER (PREOPANC-2 STUDY)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516260-29-00

Enrollment

368

Registered

2024-10-09

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-metastatic (borderline) resectable pancreatic cancer

Brief summary

The main endpoint is overall survival

Interventions

DRUGIrinotecan HCl-trihydraat Fresenius Kabi 20 mg/ml

DRUGconcentraat voor oplossing voor infusie

DRUGFolinezuur Sandoz 10 mg/ml

DRUGoplossing voor injectie

DRUGOxaliplatine Fresenius Kabi 5 mg/ml concentraat voor oplossing voor infusie

DRUGGemcitabine Sandoz 40 mg/ml

DRUGFluorouracil Accord 50 mg/ml

DRUGoplossing voor injectie of infusie

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The main endpoint is overall survival	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026